Study Title
ARST1921: A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014) in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors
Protocol ID
ARST1921
Disease (Sub Disease)
Desmoid Fibromatosis
Recurrent Desmoid Fibromatosis
Unresectable Desmoid Fibromatosis
Recurrent Desmoid Fibromatosis
Unresectable Desmoid Fibromatosis
Diagnosis Stage
New Diagnosis
Relapse
Relapse
Location
NZ
Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc.
Links
Trial Status
Open
Sites
Christchurch Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
12 Months to 18 Years
International registry ID's
NCT04195399
| Study Title | ARST1921: A Safety Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor Nirogacestat (PF-03084014) in Children and Adolescents With Progressive Surgically Unresectable Desmoid Tumors |
|---|---|
| Protocol ID | ARST1921 |
| Disease (Sub Disease) | Desmoid Fibromatosis Recurrent Desmoid Fibromatosis Unresectable Desmoid Fibromatosis |
| Diagnosis Stage | New Diagnosis Relapse |
| Location | NZ |
| Sponsor | Children's Oncology Group |
| Collaborators | National Cancer Institute (NCI)/ SpringWorks Therapeutics, Inc. |
| Links | https://clinicaltrials.gov/ct2/show/NCT04195399 |
| Trial Status | Open |
| Trial Open Date | 21/09/2020 |
| Sites | Christchurch Hospital |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 12 Months to 18 Years |
| International registry ID's | NCT04195399 |